Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 7/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 4/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23957654 | 0.88 | GBA1 (0.39) | GBA1NPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL23957702 | 0.80 | LPL (0.34) | CACNA1H | |
| SCHEMBL30452646 | 0.79 | TDO2 (0.37) | GBA1NPC1ALDH1A1KDM4EEGLN1 | |
| SCHEMBL28431647 | 0.79 | TDO2 (0.37) | GBA1NPC1ALDH1A1KDM4EEGLN1 | |
| Ammonia Solution, Strong SCHEMBL22041901 | 0.76 | EGLN1 (0.39) | KDM4ERETEGLN1 | |
| SCHEMBL23930010 | 0.75 | GBA1 (0.39) | GBA1RETEGLN1 | |
| SCHEMBL30175285 | 0.75 | GBA1 (0.39) | GBA1RETEGLN1 | |
| SCHEMBL23957687 | 0.75 | GBA1 (0.39) | GBA1RETEGLN1 | |
| Hydrochloric Acid SCHEMBL28716738 | 0.75 | EGLN1 (0.38) | KDM4ERETEGLN1 | |
| SCHEMBL21745145 | 0.75 | EGLN1 (0.39) | KDM4ERETEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115605477-B | Pyrazolo [1,5-a ] pyridine derivative, preparation method, composition and application thereof | 深圳众格生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4141003-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Shenzhen Zhongge Biological Technology Co., Ltd. (CN) | 2023-03-01 | — | — | EP | disclosed |
| EP-4141003-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Shenzhen Zhongge Biological Technology Co., Ltd. (CN) | 2023-03-01 | — | — | EP | disclosed |
| CN-115605477-A | Pyrazolo [1,5-a ] pyridine derivative and preparation method, composition and application thereof | 深圳众格生物科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2021213476-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | 深圳晶泰科技有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021213476-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | 深圳晶泰科技有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NCOA4, CCDC47, CCDC6 | GBA1 3054/4885CACNA1H 1924/4885NPC1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.